Preclinical data demonstrate that selective neutralization of TGF-beta 1 & 3 by AVID200 results in both of these critical outcomes. We believe that AVID200 has the potential to become the first ...

Drugs inhibiting TGF-β have just started clinical development and are currently in phase 1 trials. Two different approaches to inhibition are being developed, he said: an antibody directed ...

LDS results in the presence of missense mutations within either of the genes encoding receptors for TGF-β. LDS-associated mutations are predicted to reduce TGF ... 2014;124(1):79–81.